A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis

Rheumatology (Oxford). 2013 Dec;52(12):2302-4. doi: 10.1093/rheumatology/ket175. Epub 2013 May 9.

Authors

Ian N Glaspole¹, Ryan F Hoy, Peter F Ryan

Affiliation

¹ Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Commercial Road, Melbourne 3004, Australia. i.glaspole@alfred.org.au.

PMID: 23661426
DOI: 10.1093/rheumatology/ket175

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / adverse effects*
Antirheumatic Agents / adverse effects*
Arthritis, Rheumatoid / drug therapy*
Certolizumab Pegol
Female
Humans
Immunoglobulin Fab Fragments / adverse effects*
Immunosuppressive Agents / adverse effects*
Lung Diseases, Interstitial / chemically induced*
Polyethylene Glycols / adverse effects*

Substances

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Immunoglobulin Fab Fragments
Immunosuppressive Agents
Polyethylene Glycols
Certolizumab Pegol